Sensitivity diagnosis of molecular target drugs for oral cancer
| Project/Area Number |
21791990
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
AOTA Keiko Osaka University, 歯学部附属病院, 医員 (70437391)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 口腔扁平上皮癌 / ABL1 / イマチニブ / ニロチニブ / RNA干渉 / 口腔癌 / グクベック / 分子標的薬感受性診断 |
|---|
| Research Abstract |
This study have attempted to apply molecular target drugs to treatment with oral cancer. First, we examined the expression of target molecules of various molecular target drugs. ABL1 was commonly overexpressed in all cell lines. Next, we tested the sensitivity of Imatinib and Nilotinib targeting ABL1 against oral squamous cell carcinomas. Nilotinib showed the growth inhibitory effect. These results suggest that Nilotinib can be applied in treatment with oral cancer by evaluating its sensitivity against each case.
|
Report
(3 results)
Research Products
(9 results)
